ERSIAS Trial
(2020)Objective
To evaluate the safety and efficacy of encephaloduroarteriosynangiosis (EDAS) in symptomatic intracranial atherosclerotic disease.
Study Summary
• ERSIAS provided evidence that EDAS combined with intensive medical management is safe and may reduce stroke risk in patients with intracranial stenosis..
Intervention
EDAS plus Intensive Medical Therapy.
Inclusion Criteria
Patients with symptomatic intracranial atherosclerosis.
Study Design
Arms: EDAS + Medical Therapy
Patients per Arm: 52 patients
Outcome
Primary Outcome:
• The composite endpoint of stroke or periprocedural death occurred in 9.6% of patients.
Secondary Outcomes:
• Functional independence (mRS 0-2 at 90 days) was achieved in 68% of patients.
• The recurrent stroke rate at 1-year follow-up was 7.5%.
• Cerebral perfusion improved, with a mean increase in cerebral blood flow (CBF) of 18% on follow-up imaging.
• The composite endpoint of stroke or periprocedural death occurred in 9.6% of patients.
Secondary Outcomes:
• Functional independence (mRS 0-2 at 90 days) was achieved in 68% of patients.
• The recurrent stroke rate at 1-year follow-up was 7.5%.
• Cerebral perfusion improved, with a mean increase in cerebral blood flow (CBF) of 18% on follow-up imaging.